Light Therapy is an area of great interest and hope for PwP worldwide, as shown by the viewing numbers. Here in this interview with Dr Wayne Markman, CEO of SYMBYX, we explore how photobiomodulation devices directly address the gut, vagus nerve and brain.
SYMBYX’s mission is to develop medically approved light therapies to reduce chronic Parkinson’s symptoms – early trials and clinical data show improvements across a range of symptoms and with a very high safety profile. SYMBYX are committed to increasing clinical trial evidence supporting light therapy as a complementary and effective intervention that fits into a person with Parkinson’s medication, healthy diet and exercise regime.
With a focus on the gut-brain axis, SYMBYX is committed to providing complementary and effective interventions for Parkinson’s patients worldwide.
SYMBYX has a range of approved medical devices for the reduction of Parkinson’s. By next year, SYMBYX will have completed 4 clinical trials with publications in leading peer reviewed journals and commenced 3 additional large scale randomised control trials investigating motor, non-motor and medication efficacy implications of infrared laser treatment to the gut.
source
